Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

23.52 -0.50 (-2.09%)
Streaming Delayed Price Updated: 12:14 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 Next >
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Reverse Stock Split
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Research illustrates company’s progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.